Wafa Akkad, MD
Family Medicine · Fairfield Township, OHNPI 1578739405
Payments from drug & device makers
Across 264 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$355
- Novo Nordisk$349
- GSK$250
- Amgen$240
- Merck$161
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,623100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $1,136 |
| AstraZeneca | 21 | $355 |
| Novo Nordisk | 23 | $349 |
| GSK | 19 | $250 |
| Amgen | 11 | $240 |
| Merck | 13 | $161 |
| Lilly USA, LLC | 9 | $147 |
| Amarin Pharma, Inc. | 8 | $118 |
| Astellas Pharma US Inc | 5 | $110 |
| Boehringer Ingelheim | 7 | $106 |
| Johnson & Johnson | 7 | $97 |
| Pfizer | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Bayer | 2 | $28 |
| Novartis | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Circassia Inc. | 2 | $25 |
| Exact Sciences | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$3,634 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 90 | $124,470 |
| EliquisApixaban | 60 | $74,994 |
| JardianceEmpagliflozin | 37 | $63,786 |
| TrulicityDulaglutide | 22 | $54,466 |
| OzempicSemaglutide | 39 | $46,959 |
| XareltoRivaroxaban | 22 | $30,166 |
| FarxigaDapagliflozin Propanediol | 26 | $29,531 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $20,440 |
| MyrbetriqMirabegron | 16 | $18,870 |
| Nurtec OdtRimegepant Sulfate | 14 | $18,315 |
| MounjaroTirzepatide | 12 | $18,289 |
| Victoza 3-PakLiraglutide | 14 | $15,592 |
| LinzessLinaclotide | 19 | $13,213 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $8,054 |
| VascepaIcosapent Ethyl | 11 | $8,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $161 | $131,233102 claims |
| PfizerEliquis, Nurtec Odt | $77 | $93,30974 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $72,75534 claims |
| Boehringer IngelheimJardiance | $106 | $63,78637 claims |
| Novo NordiskOzempic | $349 | $46,95939 claims |
| Johnson & JohnsonXarelto | $97 | $30,16622 claims |
| AstraZenecaFarxiga | $355 | $29,53126 claims |
| GSKBreo Ellipta, Anoro Ellipta | $250 | $28,49361 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $18,87016 claims |
| AbbVieLinzess | $1,136 | $13,21319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fairfield Township
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.